Global Biopharmaceutical Contract Manufacturing Market By Therapeutic Area (Autoimmune Diseases, Oncology, Metabolic Diseases, Ophthalmology, Cardiovascular Diseases, Infectious Diseases, Neurology, Respiratory Disorders, Others); By Platform (Mammalian, Microbial); By Product Type (Growth Factors, Interferons, Monoclonal Antibodies, Recombinant Hormones, Vaccines, Insulin, Others); By Application (Clinical, Commercial, Active Pharmaceutical Ingredient (API), Finish Product); By Region (U.S., Canada, Mexico, Rest of North America, France, UK, Germany, Spain, Italy, Nordic Countries, Benelux Union, Rest of Europe, China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Rest of Asia Pacific, Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of MEA, Brazil, Argentina, Rest of Latin America) – Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2019 – 2027
Industry Trends
Biopharmaceutical Contract Manufacturing Market was valued at US$ 10.4 billion in 2018 and is set to grow at a CAGR of around 16% by 2027. Pharmaceutical manufacturing processes have been an area of focus over the years in an attempt to expedite the overall production time for various medicines and allied products. Pharmaceutical companies have been actively investing in medical research for synthesizing cures and preventive measures for ailments. Also, investments have been targeted towards improving the processes through which these products are products or developed.
Biopharmaceuticals are dedicated medicinal products that are extracted through procedures on biological source materials. The sources for biopharmaceutical products include animals, humans, and micro-organisms. The investments towards the synthesis of biopharmaceuticals are significant owing to the non-traditional approach towards the selection of sources. This leads to changes in estimation for the costs and time required for product development as compared to traditional pharmaceutical products. Hence, companies invest more focus on improved productivity in the development of biopharmaceutical products. Once the products have been synthesized and receive regulatory approvals, production kick-off is undertaken to send the products to the medical Biopharmaceutical Contract Manufacturing Market. In doing the same, companies look towards improving their manufacturing capabilities by either enhancing their existing production setups or seeking contractual services for manufacturing from dedicated service providers. Contract manufacturing is defined as the production of products in a facility under a licensing agreement with another company. The adoption of contract manufacturing in the pharmaceutical industry has helped traditional pharmaceutical manufacturers to cope with the surge in product demand by distributing production responsibilities amongst their own production teams and their contractual production partners. Companies such as Samsung Biologics Co., Ltd., Lonza, Boehringer Ingelheim International GmbH and AbbVie Inc. have portrayed significant production capabilities for biopharmaceutical products. These companies account for the lion’s share of capacities to produce biopharmaceuticals on a global scale.
Some of the notable biopharmaceutical products which are manufactured using contract manufacturing include growth factors, interferons, monoclonal antibodies, recombinant hormones, vaccines, and Insulin amongst others. These products are responsible for helping the curation and prevention of various diseases and conditions on a global level. Biopharmaceutical products are manufactured as finished products or as an active pharmaceutical ingredient (API). These products are used in various medical disciplines including Oncology, Cardiology, and Ophthalmology, amongst others. Research is being undertaken to improve the expanse of medical areas where biopharmaceuticals can be applied and companies are awaiting regulatory clearances for starting production on various products in their current pipeline. These initiatives are expected to aid the growth of the biopharmaceutical contract pharmaceutical manufacturing market.
In terms of revenue, the global biopharmaceutical contract manufacturing market stood at around US$ 10.40 Bn in 2018 and is anticipated to reach around US$ 35.80 Bn by 2027, expanding at a CAGR of 14.9% during the forecast period. The study analyzes the market in terms of revenue across all the major regions, which is further bifurcated into countries.
Global Biopharmaceutical Contract Manufacturing Market Revenue & Forecast, (US$ Billion), 2015 – 2027
Competitive Landscape
The report provides both, qualitative and quantitative research on biopharmaceutical contract manufacturing market, as well as provides comprehensive insights and favored development methods adopted by the key contenders. The report also offers extensive research on the key players in this Biopharmaceutical Contract Manufacturing Market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analyzed in the report. For each company, the report studies their global presence, competitors, service offerings and specifications.
The primary Biopharmaceutical Contract Manufacturing Market include AbbVie Inc., Abzena Ltd, Ajinomoto Bio-Pharma, Baxter Healthcare Corporation, Boehringer Ingelheim International GmbH, Catalent, Inc., Cytovance Biologics, FUJIFILM Corporation, KBI Biopharma, Lonza, ProBioGen AG, Rentschler Biopharma SE, Sai Life Sciences Ltd., Samsung Biologics Co., Ltd., Sandoz International GmbH, Thermo Fisher Scientific Inc (Patheon), Vetter, WuXi Biologics, amongst several others.
Global Biopharmaceutical Contract Manufacturing Market:
- By Therapeutic Area
- Autoimmune Diseases
- Oncology
- Metabolic Diseases
- Ophthalmology
- Cardiovascular Diseases
- Infectious Diseases
- Neurology
- Respiratory Disorders
- Others
- By Platform
- Mammalian
- Microbial
- By Product Type
- Growth Factors
- Interferons
- Monoclonal Antibodies
- Recombinant Hormones
- Vaccines
- Insulin
- Others
- By Application
- Clinical
- Commercial
- Active Pharmaceutical Ingredient (API)
- Finish Product
- By Region
- North America
- U.S.
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of South Asia
- Rest of Asia Pacific
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
- North America
1.
Market Scope
1.1. Market
Segmentation
1.2. Years
Considered
1.2.1. Historic
Years: 2015 - 2017
1.2.2. Base
Year: 2018
1.2.3. Forecast
Years: 2019 – 2027
2.
Key Target Audiences
3.
Research Methodology
3.1. Primary
Research
3.1.1. Research
Questionnaire
3.1.2. Global
Percentage Breakdown
3.1.3. Primary
Interviews: Key Opinion Leaders (KOLs)
3.2. Secondary
Research
3.2.1. Paid
Databases
3.2.2. Secondary
Sources
3.3. Market
Size Estimates
3.3.1. Top-Down
Approach
3.3.2. Bottom-Up
Approach
3.4. Data
Triangulation Methodology
3.5. Research
Assumptions
4.
Recommendations and
Insights from AMI’s Perspective**
5.
Holistic Overview of
Biopharmaceutical Contract Manufacturing Market
6.
Market Synopsis: Biopharmaceutical Contract Manufacturing
Market
7.
Biopharmaceutical Contract
Manufacturing Market Analysis: Qualitative Perspective
7.1. Introduction
7.1.1. Product Definition
7.1.2. Industry
Development
7.2. Market
Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.3. Trends in
Biopharmaceutical Contract Manufacturing Market
7.4. Market
Determinants Radar Chart
7.5. Macro-Economic
and Micro-Economic Indicators: Biopharmaceutical Contract Manufacturing Market
7.6. Porter’s
Five Force Analysis
8.
Global Biopharmaceutical
Contract Manufacturing Market Analysis and Forecasts, 2019 – 2027
8.1. Overview
8.1.1. Global
Biopharmaceutical Contract Manufacturing Market Revenue (US$ Mn)
8.2. Global
Biopharmaceutical Contract Manufacturing Market Revenue (US$ Mn) and Forecasts,
By Therapeutic Area
8.2.1. Autoimmune
Diseases
8.2.1.1. Definition
8.2.1.2. Market Estimation and Penetration, 2015 – 2018
8.2.1.3. Market Forecast, 2019 – 2027
8.2.1.4. Compound Annual Growth Rate (CAGR)
8.2.1.5. Regional Bifurcation
8.2.1.5.1. North America
8.2.1.5.1.1. Market
Estimation, 2015 – 2018
8.2.1.5.1.2. Market
Forecast, 2019 – 2027
8.2.1.5.2. Europe
8.2.1.5.2.1. Market
Estimation, 2015 – 2018
8.2.1.5.2.2. Market
Forecast, 2019 – 2027
8.2.1.5.3. Asia Pacific
8.2.1.5.3.1. Market
Estimation, 2015 – 2018
8.2.1.5.3.2. Market
Forecast, 2019 – 2027
8.2.1.5.4. Middle East and Africa
8.2.1.5.4.1. Market
Estimation, 2015 – 2018
8.2.1.5.4.2. Market
Forecast, 2019 – 2027
8.2.1.5.5. Latin America
8.2.1.5.5.1. Market
Estimation, 2015 – 2018
8.2.1.5.5.2. Market
Forecast, 2019 – 2027
8.2.2. Oncology
8.2.2.1. Definition
8.2.2.2. Market Estimation and Penetration, 2015 – 2018
8.2.2.3. Market Forecast, 2019 – 2027
8.2.2.4. Compound Annual Growth Rate (CAGR)
8.2.2.5. Regional Bifurcation
8.2.2.5.1. North America
8.2.2.5.1.1. Market
Estimation, 2015 – 2018
8.2.2.5.1.2. Market
Forecast, 2019 – 2027
8.2.2.5.2. Europe
8.2.2.5.2.1. Market
Estimation, 2015 – 2018
8.2.2.5.2.2. Market
Forecast, 2019 – 2027
8.2.2.5.3. Asia Pacific
8.2.2.5.3.1. Market
Estimation, 2015 – 2018
8.2.2.5.3.2. Market
Forecast, 2019 – 2027
8.2.2.5.4. Middle East and Africa
8.2.2.5.4.1. Market
Estimation, 2015 – 2018
8.2.2.5.4.2. Market
Forecast, 2019 – 2027
8.2.2.5.5. Latin America
8.2.2.5.5.1. Market
Estimation, 2015 – 2018
8.2.2.5.5.2. Market
Forecast, 2019 – 2027
8.2.3. Metabolic
Diseases
8.2.3.1. Definition
8.2.3.2. Market Estimation and Penetration, 2015 – 2018
8.2.3.3. Market Forecast, 2019 – 2027
8.2.3.4. Compound Annual Growth Rate (CAGR)
8.2.3.5. Regional Bifurcation
8.2.3.5.1. North America
8.2.3.5.1.1. Market
Estimation, 2015 – 2018
8.2.3.5.1.2. Market
Forecast, 2019 – 2027
8.2.3.5.2. Europe
8.2.3.5.2.1. Market
Estimation, 2015 – 2018
8.2.3.5.2.2. Market
Forecast, 2019 – 2027
8.2.3.5.3. Asia Pacific
8.2.3.5.3.1. Market
Estimation, 2015 – 2018
8.2.3.5.3.2. Market
Forecast, 2019 – 2027
8.2.3.5.4. Middle East and Africa
8.2.3.5.4.1. Market
Estimation, 2015 – 2018
8.2.3.5.4.2. Market
Forecast, 2019 – 2027
8.2.3.5.5. Latin America
8.2.3.5.5.1. Market
Estimation, 2015 – 2018
8.2.3.5.5.2. Market
Forecast, 2019 – 2027
8.2.4. Ophthalmology
8.2.4.1. Definition
8.2.4.2. Market Estimation and Penetration, 2015 – 2018
8.2.4.3. Market Forecast, 2019 – 2027
8.2.4.4. Compound Annual Growth Rate (CAGR)
8.2.4.5. Regional Bifurcation
8.2.4.5.1. North America
8.2.4.5.1.1. Market
Estimation, 2015 – 2018
8.2.4.5.1.2. Market
Forecast, 2019 – 2027
8.2.4.5.2. Europe
8.2.4.5.2.1. Market
Estimation, 2015 – 2018
8.2.4.5.2.2. Market
Forecast, 2019 – 2027
8.2.4.5.3. Asia Pacific
8.2.4.5.3.1. Market
Estimation, 2015 – 2018
8.2.4.5.3.2. Market
Forecast, 2019 – 2027
8.2.4.5.4. Middle East and Africa
8.2.4.5.4.1. Market
Estimation, 2015 – 2018
8.2.4.5.4.2. Market
Forecast, 2019 – 2027
8.2.4.5.5. Latin America
8.2.4.5.5.1. Market
Estimation, 2015 – 2018
8.2.4.5.5.2. Market
Forecast, 2019 – 2027
8.2.5. Cardiovascular
Diseases
8.2.5.1. Definition
8.2.5.2. Market Estimation and Penetration, 2015 – 2018
8.2.5.3. Market Forecast, 2019 – 2027
8.2.5.4. Compound Annual Growth Rate (CAGR)
8.2.5.5. Regional Bifurcation
8.2.5.5.1. North America
8.2.5.5.1.1. Market
Estimation, 2015 – 2018
8.2.5.5.1.2. Market
Forecast, 2019 – 2027
8.2.5.5.2. Europe
8.2.5.5.2.1. Market
Estimation, 2015 – 2018
8.2.5.5.2.2. Market
Forecast, 2019 – 2027
8.2.5.5.3. Asia Pacific
8.2.5.5.3.1. Market
Estimation, 2015 – 2018
8.2.5.5.3.2. Market
Forecast, 2019 – 2027
8.2.5.5.4. Middle East and Africa
8.2.5.5.4.1. Market
Estimation, 2015 – 2018
8.2.5.5.4.2. Market
Forecast, 2019 – 2027
8.2.5.5.5. Latin America
8.2.5.5.5.1. Market
Estimation, 2015 – 2018
8.2.5.5.5.2. Market
Forecast, 2019 – 2027
8.2.6. Infectious
Diseases
8.2.6.1. Definition
8.2.6.2. Market Estimation and Penetration, 2015 – 2018
8.2.6.3. Market Forecast, 2019 – 2027
8.2.6.4. Compound Annual Growth Rate (CAGR)
8.2.6.5. Regional Bifurcation
8.2.6.5.1. North America
8.2.6.5.1.1. Market
Estimation, 2015 – 2018
8.2.6.5.1.2. Market
Forecast, 2019 – 2027
8.2.6.5.2. Europe
8.2.6.5.2.1. Market
Estimation, 2015 – 2018
8.2.6.5.2.2. Market
Forecast, 2019 – 2027
8.2.6.5.3. Asia Pacific
8.2.6.5.3.1. Market
Estimation, 2015 – 2018
8.2.6.5.3.2. Market
Forecast, 2019 – 2027
8.2.6.5.4. Middle East and Africa
8.2.6.5.4.1. Market
Estimation, 2015 – 2018
8.2.6.5.4.2. Market
Forecast, 2019 – 2027
8.2.6.5.5. Latin America
8.2.6.5.5.1. Market
Estimation, 2015 – 2018
8.2.6.5.5.2. Market
Forecast, 2019 – 2027
8.2.7. Neurology
8.2.7.1. Definition
8.2.7.2. Market Estimation and Penetration, 2015 – 2018
8.2.7.3. Market Forecast, 2019 – 2027
8.2.7.4. Compound Annual Growth Rate (CAGR)
8.2.7.5. Regional Bifurcation
8.2.7.5.1. North America
8.2.7.5.1.1. Market
Estimation, 2015 – 2018
8.2.7.5.1.2. Market
Forecast, 2019 – 2027
8.2.7.5.2. Europe
8.2.7.5.2.1. Market
Estimation, 2015 – 2018
8.2.7.5.2.2. Market
Forecast, 2019 – 2027
8.2.7.5.3. Asia Pacific
8.2.7.5.3.1. Market
Estimation, 2015 – 2018
8.2.7.5.3.2. Market
Forecast, 2019 – 2027
8.2.7.5.4. Middle East and Africa
8.2.7.5.4.1. Market
Estimation, 2015 – 2018
8.2.7.5.4.2. Market
Forecast, 2019 – 2027
8.2.7.5.5. Latin America
8.2.7.5.5.1. Market
Estimation, 2015 – 2018
8.2.7.5.5.2. Market
Forecast, 2019 – 2027
8.2.8. Respiratory
Disorders
8.2.8.1. Definition
8.2.8.2. Market Estimation and Penetration, 2015 – 2018
8.2.8.3. Market Forecast, 2019 – 2027
8.2.8.4. Compound Annual Growth Rate (CAGR)
8.2.8.5. Regional Bifurcation
8.2.8.5.1. North America
8.2.8.5.1.1. Market
Estimation, 2015 – 2018
8.2.8.5.1.2. Market
Forecast, 2019 – 2027
8.2.8.5.2. Europe
8.2.8.5.2.1. Market
Estimation, 2015 – 2018
8.2.8.5.2.2. Market
Forecast, 2019 – 2027
8.2.8.5.3. Asia Pacific
8.2.8.5.3.1. Market
Estimation, 2015 – 2018
8.2.8.5.3.2. Market
Forecast, 2019 – 2027
8.2.8.5.4. Middle East and Africa
8.2.8.5.4.1. Market
Estimation, 2015 – 2018
8.2.8.5.4.2. Market
Forecast, 2019 – 2027
8.2.8.5.5. Latin America
8.2.8.5.5.1. Market
Estimation, 2015 – 2018
8.2.8.5.5.2. Market
Forecast, 2019 – 2027
8.2.9. Others
8.2.9.1. Definition
8.2.9.2. Market Estimation and Penetration, 2015 – 2018
8.2.9.3. Market Forecast, 2019 – 2027
8.2.9.4. Compound Annual Growth Rate (CAGR)
8.2.9.5. Regional Bifurcation
8.2.9.5.1. North America
8.2.9.5.1.1. Market
Estimation, 2015 – 2018
8.2.9.5.1.2. Market
Forecast, 2019 – 2027
8.2.9.5.2. Europe
8.2.9.5.2.1. Market
Estimation, 2015 – 2018
8.2.9.5.2.2. Market
Forecast, 2019 – 2027
8.2.9.5.3. Asia Pacific
8.2.9.5.3.1. Market
Estimation, 2015 – 2018
8.2.9.5.3.2. Market
Forecast, 2019 – 2027
8.2.9.5.4. Middle East and Africa
8.2.9.5.4.1. Market
Estimation, 2015 – 2018
8.2.9.5.4.2. Market
Forecast, 2019 – 2027
8.2.9.5.5. Latin America
8.2.9.5.5.1. Market
Estimation, 2015 – 2018
8.2.9.5.5.2. Market
Forecast, 2019 – 2027
8.3. Key
Segment for Channeling Investments
8.3.1. By
Therapeutic Area
9.
Global Biopharmaceutical Contract
Manufacturing Market Analysis and Forecasts, 2019 – 2027
9.1. Overview
9.2. Global
Biopharmaceutical Contract Manufacturing Market Revenue (US$ Mn) and Forecasts,
By Platform
9.2.1. Mammalian
9.2.1.1. Definition
9.2.1.2. Market Estimation and Penetration, 2015 – 2018
9.2.1.3. Market Forecast, 2019 – 2027
9.2.1.4. Compound Annual Growth Rate (CAGR)
9.2.1.5. Regional Bifurcation
9.2.1.5.1. North America
9.2.1.5.1.1. Market
Estimation, 2015 – 2018
9.2.1.5.1.2. Market
Forecast, 2019 – 2027
9.2.1.5.2. Europe
9.2.1.5.2.1. Market
Estimation, 2015 – 2018
9.2.1.5.2.2. Market
Forecast, 2019 – 2027
9.2.1.5.3. Asia Pacific
9.2.1.5.3.1. Market
Estimation, 2015 – 2018
9.2.1.5.3.2. Market
Forecast, 2019 – 2027
9.2.1.5.4. Middle East and Africa
9.2.1.5.4.1. Market
Estimation, 2015 – 2018
9.2.1.5.4.2. Market
Forecast, 2019 – 2027
9.2.1.5.5. Latin America
9.2.1.5.5.1. Market
Estimation, 2015 – 2018
9.2.1.5.5.2. Market
Forecast, 2019 – 2027
9.2.2. Microbial
9.2.2.1. Definition
9.2.2.2. Market Estimation and Penetration, 2015 – 2018
9.2.2.3. Market Forecast, 2019 – 2027
9.2.2.4. Compound Annual Growth Rate (CAGR)
9.2.2.5. Regional Bifurcation
9.2.2.5.1. North America
9.2.2.5.1.1. Market
Estimation, 2015 – 2018
9.2.2.5.1.2. Market
Forecast, 2019 – 2027
9.2.2.5.2. Europe
9.2.2.5.2.1. Market
Estimation, 2015 – 2018
9.2.2.5.2.2. Market
Forecast, 2019 – 2027
9.2.2.5.3. Asia Pacific
9.2.2.5.3.1. Market
Estimation, 2015 – 2018
9.2.2.5.3.2. Market
Forecast, 2019 – 2027
9.2.2.5.4. Middle East and Africa
9.2.2.5.4.1. Market
Estimation, 2015 – 2018
9.2.2.5.4.2. Market
Forecast, 2019 – 2027
9.2.2.5.5. Latin America
9.2.2.5.5.1. Market
Estimation, 2015 – 2018
9.2.2.5.5.2. Market
Forecast, 2019 – 2027
9.3. Key
Segment for Channeling Investments
9.3.1. By
Platform
10.
Global Biopharmaceutical
Contract Manufacturing Market Analysis and Forecasts, 2019 – 2027
10.1. Overview
10.2. Global
Biopharmaceutical Contract Manufacturing Market Revenue (US$ Mn) and Forecasts,
By Microbial
10.2.1. Growth
Factors
10.2.1.1. Definition
10.2.1.2. Market Estimation and Penetration, 2015 – 2018
10.2.1.3. Market Forecast, 2019 – 2027
10.2.1.4. Compound Annual Growth Rate (CAGR)
10.2.1.5. Regional Bifurcation
10.2.1.5.1. North America
10.2.1.5.1.1. Market
Estimation, 2015 – 2018
10.2.1.5.1.2. Market
Forecast, 2019 – 2027
10.2.1.5.2. Europe
10.2.1.5.2.1. Market
Estimation, 2015 – 2018
10.2.1.5.2.2. Market
Forecast, 2019 – 2027
10.2.1.5.3. Asia Pacific
10.2.1.5.3.1. Market
Estimation, 2015 – 2018
10.2.1.5.3.2. Market
Forecast, 2019 – 2027
10.2.1.5.4. Middle East and Africa
10.2.1.5.4.1. Market
Estimation, 2015 – 2018
10.2.1.5.4.2. Market
Forecast, 2019 – 2027
10.2.1.5.5. Latin America
10.2.1.5.5.1. Market
Estimation, 2015 – 2018
10.2.1.5.5.2. Market
Forecast, 2019 – 2027
10.2.2. Interferons
10.2.2.1. Definition
10.2.2.2. Market Estimation and Penetration, 2015 – 2018
10.2.2.3. Market Forecast, 2019 – 2027
10.2.2.4. Compound Annual Growth Rate (CAGR)
10.2.2.5. Regional Bifurcation
10.2.2.5.1. North America
10.2.2.5.1.1. Market
Estimation, 2015 – 2018
10.2.2.5.1.2. Market
Forecast, 2019 – 2027
10.2.2.5.2. Europe
10.2.2.5.2.1. Market
Estimation, 2015 – 2018
10.2.2.5.2.2. Market
Forecast, 2019 – 2027
10.2.2.5.3. Asia Pacific
10.2.2.5.3.1. Market
Estimation, 2015 – 2018
10.2.2.5.3.2. Market
Forecast, 2019 – 2027
10.2.2.5.4. Middle East and Africa
10.2.2.5.4.1. Market
Estimation, 2015 – 2018
10.2.2.5.4.2. Market
Forecast, 2019 – 2027
10.2.2.5.5. Latin America
10.2.2.5.5.1. Market
Estimation, 2015 – 2018
10.2.2.5.5.2. Market
Forecast, 2019 – 2027
10.2.3. Monoclonal
Antibodies
10.2.3.1. Definition
10.2.3.2. Market Estimation and Penetration, 2015 – 2018
10.2.3.3. Market Forecast, 2019 – 2027
10.2.3.4. Compound Annual Growth Rate (CAGR)
10.2.3.5. Regional Bifurcation
10.2.3.5.1. North America
10.2.3.5.1.1. Market
Estimation, 2015 – 2018
10.2.3.5.1.2. Market
Forecast, 2019 – 2027
10.2.3.5.2. Europe
10.2.3.5.2.1. Market
Estimation, 2015 – 2018
10.2.3.5.2.2. Market
Forecast, 2019 – 2027
10.2.3.5.3. Asia Pacific
10.2.3.5.3.1. Market
Estimation, 2015 – 2018
10.2.3.5.3.2. Market
Forecast, 2019 – 2027
10.2.3.5.4. Middle East and Africa
10.2.3.5.4.1. Market
Estimation, 2015 – 2018
10.2.3.5.4.2. Market
Forecast, 2019 – 2027
10.2.3.5.5. Latin America
10.2.3.5.5.1. Market
Estimation, 2015 – 2018
10.2.3.5.5.2. Market
Forecast, 2019 – 2027
10.2.4. Recombinant
Hormones
10.2.4.1. Definition
10.2.4.2. Market Estimation and Penetration, 2015 – 2018
10.2.4.3. Market Forecast, 2019 – 2027
10.2.4.4. Compound Annual Growth Rate (CAGR)
10.2.4.5. Regional Bifurcation
10.2.4.5.1. North America
10.2.4.5.1.1. Market
Estimation, 2015 – 2018
10.2.4.5.1.2. Market
Forecast, 2019 – 2027
10.2.4.5.2. Europe
10.2.4.5.2.1. Market
Estimation, 2015 – 2018
10.2.4.5.2.2. Market
Forecast, 2019 – 2027
10.2.4.5.3. Asia Pacific
10.2.4.5.3.1. Market
Estimation, 2015 – 2018
10.2.4.5.3.2. Market
Forecast, 2019 – 2027
10.2.4.5.4. Middle East and Africa
10.2.4.5.4.1. Market
Estimation, 2015 – 2018
10.2.4.5.4.2. Market
Forecast, 2019 – 2027
10.2.4.5.5. Latin America
10.2.4.5.5.1. Market
Estimation, 2015 – 2018
10.2.4.5.5.2. Market
Forecast, 2019 – 2027
10.2.5. Vaccines
10.2.5.1. Definition
10.2.5.2. Market Estimation and Penetration, 2015 – 2018
10.2.5.3. Market Forecast, 2019 – 2027
10.2.5.4. Compound Annual Growth Rate (CAGR)
10.2.5.5. Regional Bifurcation
10.2.5.5.1. North America
10.2.5.5.1.1. Market
Estimation, 2015 – 2018
10.2.5.5.1.2. Market
Forecast, 2019 – 2027
10.2.5.5.2. Europe
10.2.5.5.2.1. Market
Estimation, 2015 – 2018
10.2.5.5.2.2. Market
Forecast, 2019 – 2027
10.2.5.5.3. Asia Pacific
10.2.5.5.3.1. Market
Estimation, 2015 – 2018
10.2.5.5.3.2. Market
Forecast, 2019 – 2027
10.2.5.5.4. Middle East and Africa
10.2.5.5.4.1. Market
Estimation, 2015 – 2018
10.2.5.5.4.2. Market
Forecast, 2019 – 2027
10.2.5.5.5. Latin America
10.2.5.5.5.1. Market
Estimation, 2015 – 2018
10.2.5.5.5.2. Market
Forecast, 2019 – 2027
10.2.6. Insulin
10.2.6.1. Definition
10.2.6.2. Market Estimation and Penetration, 2015 – 2018
10.2.6.3. Market Forecast, 2019 – 2027
10.2.6.4. Compound Annual Growth Rate (CAGR)
10.2.6.5. Regional Bifurcation
10.2.6.5.1. North America
10.2.6.5.1.1. Market
Estimation, 2015 – 2018
10.2.6.5.1.2. Market
Forecast, 2019 – 2027
10.2.6.5.2. Europe
10.2.6.5.2.1. Market
Estimation, 2015 – 2018
10.2.6.5.2.2. Market
Forecast, 2019 – 2027
10.2.6.5.3. Asia Pacific
10.2.6.5.3.1. Market
Estimation, 2015 – 2018
10.2.6.5.3.2. Market
Forecast, 2019 – 2027
10.2.6.5.4. Middle East and Africa
10.2.6.5.4.1. Market
Estimation, 2015 – 2018
10.2.6.5.4.2. Market
Forecast, 2019 – 2027
10.2.6.5.5. Latin America
10.2.6.5.5.1. Market
Estimation, 2015 – 2018
10.2.6.5.5.2. Market
Forecast, 2019 – 2027
10.2.7. Others
10.2.7.1. Definition
10.2.7.2. Market Estimation and Penetration, 2015 – 2018
10.2.7.3. Market Forecast, 2019 – 2027
10.2.7.4. Compound Annual Growth Rate (CAGR)
10.2.7.5. Regional Bifurcation
10.2.7.5.1. North America
10.2.7.5.1.1. Market
Estimation, 2015 – 2018
10.2.7.5.1.2. Market
Forecast, 2019 – 2027
10.2.7.5.2. Europe
10.2.7.5.2.1. Market
Estimation, 2015 – 2018
10.2.7.5.2.2. Market
Forecast, 2019 – 2027
10.2.7.5.3. Asia Pacific
10.2.7.5.3.1. Market
Estimation, 2015 – 2018
10.2.7.5.3.2. Market
Forecast, 2019 – 2027
10.2.7.5.4. Middle East and Africa
10.2.7.5.4.1. Market
Estimation, 2015 – 2018
10.2.7.5.4.2. Market
Forecast, 2019 – 2027
10.2.7.5.5. Latin America
10.2.7.5.5.1. Market
Estimation, 2015 – 2018
10.2.7.5.5.2. Market
Forecast, 2019 – 2027
10.3. Key
Segment for Channeling Investments
10.3.1. By
Microbial
11.
Global Biopharmaceutical
Contract Manufacturing Market Analysis and Forecasts, 2019 – 2027
11.1. Overview
11.2. Global
Biopharmaceutical Contract Manufacturing Market Revenue (US$ Mn) and Forecasts,
By Application
11.2.1. Clinical
11.2.1.1. Definition
11.2.1.2. Market Estimation and Penetration, 2015 – 2018
11.2.1.3. Market Forecast, 2019 – 2027
11.2.1.4. Compound Annual Growth Rate (CAGR)
11.2.1.5. Regional Bifurcation
11.2.1.5.1. North America
11.2.1.5.1.1. Market
Estimation, 2015 – 2018
11.2.1.5.1.2. Market
Forecast, 2019 – 2027
11.2.1.5.2. Europe
11.2.1.5.2.1. Market
Estimation, 2015 – 2018
11.2.1.5.2.2. Market
Forecast, 2019 – 2027
11.2.1.5.3. Asia Pacific
11.2.1.5.3.1. Market
Estimation, 2015 – 2018
11.2.1.5.3.2. Market
Forecast, 2019 – 2027
11.2.1.5.4. Middle East and Africa
11.2.1.5.4.1. Market
Estimation, 2015 – 2018
11.2.1.5.4.2. Market
Forecast, 2019 – 2027
11.2.1.5.5. Latin America
11.2.1.5.5.1. Market
Estimation, 2015 – 2018
11.2.1.5.5.2. Market
Forecast, 2019 – 2027
11.2.2. Commercial
11.2.2.1. Definition
11.2.2.2. Market Estimation and Penetration, 2015 – 2018
11.2.2.3. Market Forecast, 2019 – 2027
11.2.2.4. Compound Annual Growth Rate (CAGR)
11.2.2.5. Regional Bifurcation
11.2.2.5.1. North America
11.2.2.5.1.1. Market
Estimation, 2015 – 2018
11.2.2.5.1.2. Market
Forecast, 2019 – 2027
11.2.2.5.2. Europe
11.2.2.5.2.1. Market
Estimation, 2015 – 2018
11.2.2.5.2.2. Market
Forecast, 2019 – 2027
11.2.2.5.3. Asia Pacific
11.2.2.5.3.1. Market
Estimation, 2015 – 2018
11.2.2.5.3.2. Market
Forecast, 2019 – 2027
11.2.2.5.4. Middle East and Africa
11.2.2.5.4.1. Market
Estimation, 2015 – 2018
11.2.2.5.4.2. Market
Forecast, 2019 – 2027
11.2.2.5.5. Latin America
11.2.2.5.5.1. Market
Estimation, 2015 – 2018
11.2.2.5.5.2. Market
Forecast, 2019 – 2027
11.2.3. Active
Pharmaceutical Ingredient (API)
11.2.3.1. Definition
11.2.3.2. Market Estimation and Penetration, 2015 – 2018
11.2.3.3. Market Forecast, 2019 – 2027
11.2.3.4. Compound Annual Growth Rate (CAGR)
11.2.3.5. Regional Bifurcation
11.2.3.5.1. North America
11.2.3.5.1.1. Market
Estimation, 2015 – 2018
11.2.3.5.1.2. Market
Forecast, 2019 – 2027
11.2.3.5.2. Europe
11.2.3.5.2.1. Market
Estimation, 2015 – 2018
11.2.3.5.2.2. Market
Forecast, 2019 – 2027
11.2.3.5.3. Asia Pacific
11.2.3.5.3.1. Market
Estimation, 2015 – 2018
11.2.3.5.3.2. Market
Forecast, 2019 – 2027
11.2.3.5.4. Middle East and Africa
11.2.3.5.4.1. Market
Estimation, 2015 – 2018
11.2.3.5.4.2. Market
Forecast, 2019 – 2027
11.2.3.5.5. Latin America
11.2.3.5.5.1. Market
Estimation, 2015 – 2018
11.2.3.5.5.2. Market
Forecast, 2019 – 2027
11.2.4. Finish
Product
11.2.4.1. Definition
11.2.4.2. Market Estimation and Penetration, 2015 – 2018
11.2.4.3. Market Forecast, 2019 – 2027
11.2.4.4. Compound Annual Growth Rate (CAGR)
11.2.4.5. Regional Bifurcation
11.2.4.5.1. North America
11.2.4.5.1.1. Market
Estimation, 2015 – 2018
11.2.4.5.1.2. Market
Forecast, 2019 – 2027
11.2.4.5.2. Europe
11.2.4.5.2.1. Market
Estimation, 2015 – 2018
11.2.4.5.2.2. Market
Forecast, 2019 – 2027
11.2.4.5.3. Asia Pacific
11.2.4.5.3.1. Market
Estimation, 2015 – 2018
11.2.4.5.3.2. Market
Forecast, 2019 – 2027
11.2.4.5.4. Middle East and Africa
11.2.4.5.4.1. Market
Estimation, 2015 – 2018
11.2.4.5.4.2. Market
Forecast, 2019 – 2027
11.2.4.5.5. Latin America
11.2.4.5.5.1. Market
Estimation, 2015 – 2018
11.2.4.5.5.2. Market
Forecast, 2019 – 2027
11.3. Key
Segment for Channeling Investments
11.3.1. By
Application
12.
North America
Biopharmaceutical Contract Manufacturing Market Analysis and Forecasts, 2019 -
2027
12.1. Overview
12.1.1. North
America Biopharmaceutical Contract Manufacturing Market Revenue (US$ Mn)
12.2. North
America Biopharmaceutical Contract Manufacturing Market Revenue (US$ Mn) and
Forecasts, By Therapeutic Area
12.2.1. Autoimmune
Diseases
12.2.2. Oncology
12.2.3. Metabolic
Diseases
12.2.4. Ophthalmology
12.2.5. Cardiovascular
Diseases
12.2.6. Infectious
Diseases
12.2.7. Neurology
12.2.8. Respiratory
Disorders
12.2.9. Others
12.3. North
America Biopharmaceutical Contract Manufacturing Market Revenue (US$ Mn) and
Forecasts, By Platform
12.3.1. Mammalian
12.3.2. Microbial
12.4. North
America Biopharmaceutical Contract Manufacturing Market Revenue (US$ Mn) and
Forecasts, By Microbial
12.4.1. Growth
Factors
12.4.2. Interferons
12.4.3. Monoclonal
Antibodies
12.4.4. Recombinant
Hormones
12.4.5. Vaccines
12.4.6. Insulin
12.4.7. Others
12.5. North
America Biopharmaceutical Contract Manufacturing Market Revenue (US$ Mn) and
Forecasts, By Application
12.5.1. Clinical
12.5.2. Commercial
12.5.3. Active
Pharmaceutical Ingredient (API)
12.5.4. Finish
Product
12.6. North
America Biopharmaceutical Contract Manufacturing Market Revenue (US$ Mn) and
Forecasts, By Country
12.6.1. U.S
12.6.1.1. U.S Biopharmaceutical Contract Manufacturing Market Revenue
(US$ Mn) and Forecasts, By Therapeutic Area
12.6.1.1.1. Autoimmune Diseases
12.6.1.1.2. Oncology
12.6.1.1.3. Metabolic Diseases
12.6.1.1.4. Ophthalmology
12.6.1.1.5. Cardiovascular Diseases
12.6.1.1.6. Infectious Diseases
12.6.1.1.7. Neurology
12.6.1.1.8. Respiratory Disorders
12.6.1.1.9. Others
12.6.1.2. U.S Biopharmaceutical Contract Manufacturing Market Revenue
(US$ Mn) and Forecasts, By Platform
12.6.1.2.1. Mammalian
12.6.1.2.2. Microbial
12.6.1.3. U.S Biopharmaceutical Contract Manufacturing Market Revenue
(US$ Mn) and Forecasts, By Microbial
12.6.1.3.1. Growth Factors
12.6.1.3.2. Interferons
12.6.1.3.3. Monoclonal Antibodies
12.6.1.3.4. Recombinant Hormones
12.6.1.3.5. Vaccines
12.6.1.3.6. Insulin
12.6.1.3.7. Others
12.6.1.4. U.S Biopharmaceutical Contract Manufacturing Market Revenue
(US$ Mn) and Forecasts, By Application
12.6.1.4.1. Clinical
12.6.1.4.2. Commercial
12.6.1.4.3. Active Pharmaceutical Ingredient (API)
12.6.1.4.4. Finish Product
12.6.2. Canada
12.6.2.1. Canada Biopharmaceutical Contract Manufacturing Market Revenue
(US$ Mn) and Forecasts, By Therapeutic Area
12.6.2.1.1. Autoimmune Diseases
12.6.2.1.2. Oncology
12.6.2.1.3. Metabolic Diseases
12.6.2.1.4. Ophthalmology
12.6.2.1.5. Cardiovascular Diseases
12.6.2.1.6. Infectious Diseases
12.6.2.1.7. Neurology
12.6.2.1.8. Respiratory Disorders
12.6.2.1.9. Others
12.6.2.2. Canada Biopharmaceutical Contract Manufacturing Market Revenue
(US$ Mn) and Forecasts, By Platform
12.6.2.2.1. Mammalian
12.6.2.2.2. Microbial
12.6.2.3. Canada Biopharmaceutical Contract Manufacturing Market Revenue
(US$ Mn) and Forecasts, By Microbial
12.6.2.3.1. Growth Factors
12.6.2.3.2. Interferons
12.6.2.3.3. Monoclonal Antibodies
12.6.2.3.4. Recombinant Hormones
12.6.2.3.5. Vaccines
12.6.2.3.6. Insulin
12.6.2.3.7. Others
12.6.2.4. Canada Biopharmaceutical Contract Manufacturing Market Revenue
(US$ Mn) and Forecasts, By Application
12.6.2.4.1. Clinical
12.6.2.4.2. Commercial
12.6.2.4.3. Active Pharmaceutical Ingredient (API)
12.6.2.4.4. Finish Product
12.6.3. Mexico
12.6.3.1. Mexico Biopharmaceutical Contract Manufacturing Market Revenue
(US$ Mn) and Forecasts, By Therapeutic Area
12.6.3.1.1. Autoimmune Diseases
12.6.3.1.2. Oncology
12.6.3.1.3. Metabolic Diseases
12.6.3.1.4. Ophthalmology
12.6.3.1.5. Cardiovascular Diseases
12.6.3.1.6. Infectious Diseases
12.6.3.1.7. Neurology
12.6.3.1.8. Respiratory Disorders
12.6.3.1.9. Others
12.6.3.2. Mexico Biopharmaceutical Contract Manufacturing Market Revenue
(US$ Mn) and Forecasts, By Platform
12.6.3.2.1. Mammalian
12.6.3.2.2. Microbial
12.6.3.3. Mexico Biopharmaceutical Contract Manufacturing Market Revenue
(US$ Mn) and Forecasts, By Microbial
12.6.3.3.1. Growth Factors
12.6.3.3.2. Interferons
12.6.3.3.3. Monoclonal Antibodies
12.6.3.3.4. Recombinant Hormones
12.6.3.3.5. Vaccines
12.6.3.3.6. Insulin
12.6.3.3.7. Others
12.6.3.4. Mexico Biopharmaceutical Contract Manufacturing Market Revenue
(US$ Mn) and Forecasts, By Application
12.6.3.4.1. Clinical
12.6.3.4.2. Commercial
12.6.3.4.3. Active Pharmaceutical Ingredient (API)
12.6.3.4.4. Finish Product
12.6.4. Rest of
North America
12.6.4.1. Rest of North America Biopharmaceutical Contract Manufacturing
Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area
12.6.4.1.1. Autoimmune Diseases
12.6.4.1.2. Oncology
12.6.4.1.3. Metabolic Diseases
12.6.4.1.4. Ophthalmology
12.6.4.1.5. Cardiovascular Diseases
12.6.4.1.6. Infectious Diseases
12.6.4.1.7. Neurology
12.6.4.1.8. Respiratory Disorders
12.6.4.1.9. Others
12.6.4.2. Rest of North America Biopharmaceutical Contract Manufacturing
Market Revenue (US$ Mn) and Forecasts, By Platform
12.6.4.2.1. Mammalian
12.6.4.2.2. Microbial
12.6.4.3. Rest of North America Biopharmaceutical Contract Manufacturing
Market Revenue (US$ Mn) and Forecasts, By Microbial
12.6.4.3.1. Growth Factors
12.6.4.3.2. Interferons
12.6.4.3.3. Monoclonal Antibodies
12.6.4.3.4. Recombinant Hormones
12.6.4.3.5. Vaccines
12.6.4.3.6. Insulin
12.6.4.3.7. Others
12.6.4.4. Rest of North America Biopharmaceutical Contract Manufacturing
Market Revenue (US$ Mn) and Forecasts, By Application
12.6.4.4.1. Clinical
12.6.4.4.2. Commercial
12.6.4.4.3. Active Pharmaceutical Ingredient (API)
12.6.4.4.4. Finish Product
12.7. Key
Segment for Channeling Investments
12.7.1. By
Country
12.7.2. By
Therapeutic Area
12.7.3. By
Platform
12.7.4. By
Microbial
12.7.5. By
Application
13.
Europe Biopharmaceutical
Contract Manufacturing Market Analysis and Forecasts, 2019 - 2027
13.1. Overview
13.1.1. Europe
Biopharmaceutical Contract Manufacturing Market Revenue (US$ Mn)
13.2. Europe
Biopharmaceutical Contract Manufacturing Market Revenue (US$ Mn) and Forecasts,
By Therapeutic Area
13.2.1. Autoimmune
Diseases
13.2.2. Oncology
13.2.3. Metabolic
Diseases
13.2.4. Ophthalmology
13.2.5. Cardiovascular
Diseases
13.2.6. Infectious
Diseases
13.2.7. Neurology
13.2.8. Respiratory
Disorders
13.2.9. Others
13.3. Europe
Biopharmaceutical Contract Manufacturing Market Revenue (US$ Mn) and Forecasts,
By Platform
13.3.1. Mammalian
13.3.2. Microbial
13.4. Europe
Biopharmaceutical Contract Manufacturing Market Revenue (US$ Mn) and Forecasts,
By Microbial
13.4.1. Growth
Factors
13.4.2. Interferons
13.4.3. Monoclonal
Antibodies
13.4.4. Recombinant
Hormones
13.4.5. Vaccines
13.4.6. Insulin
13.4.7. Others
13.5. Europe
Biopharmaceutical Contract Manufacturing Market Revenue (US$ Mn) and Forecasts,
By Application
13.5.1. Clinical
13.5.2. Commercial
13.5.3. Active Pharmaceutical
Ingredient (API)
13.5.4. Finish
Product
13.6. Europe
Biopharmaceutical Contract Manufacturing Market Revenue (US$ Mn) and Forecasts,
By Country
13.6.1. France
13.6.1.1. France Biopharmaceutical Contract Manufacturing Market Revenue
(US$ Mn) and Forecasts, By Therapeutic Area
13.6.1.1.1. Autoimmune Diseases
13.6.1.1.2. Oncology
13.6.1.1.3. Metabolic Diseases
13.6.1.1.4. Ophthalmology
13.6.1.1.5. Cardiovascular Diseases
13.6.1.1.6. Infectious Diseases
13.6.1.1.7. Neurology
13.6.1.1.8. Respiratory Disorders
13.6.1.1.9. Others
13.6.1.2. France Biopharmaceutical Contract Manufacturing Market Revenue
(US$ Mn) and Forecasts, By Platform
13.6.1.2.1. Mammalian
13.6.1.2.2. Microbial
13.6.1.3. France Biopharmaceutical Contract Manufacturing Market Revenue
(US$ Mn) and Forecasts, By Microbial
13.6.1.3.1. Growth Factors
13.6.1.3.2. Interferons
13.6.1.3.3. Monoclonal Antibodies
13.6.1.3.4. Recombinant Hormones
13.6.1.3.5. Vaccines
13.6.1.3.6. Insulin
13.6.1.3.7. Others
13.6.1.4. France Biopharmaceutical Contract Manufacturing Market Revenue
(US$ Mn) and Forecasts, By Application
13.6.1.4.1. Clinical
13.6.1.4.2. Commercial
13.6.1.4.3. Active Pharmaceutical Ingredient (API)
13.6.1.4.4. Finish Product
13.6.2. The UK
13.6.2.1. The UK Biopharmaceutical Contract Manufacturing Market Revenue
(US$ Mn) and Forecasts, By Therapeutic Area
13.6.2.1.1. Autoimmune Diseases
13.6.2.1.2. Oncology
13.6.2.1.3. Metabolic Diseases
13.6.2.1.4. Ophthalmology
13.6.2.1.5. Cardiovascular Diseases
13.6.2.1.6. Infectious Diseases
13.6.2.1.7. Neurology
13.6.2.1.8. Respiratory Disorders
13.6.2.1.9. Others
13.6.2.2. The UK Biopharmaceutical Contract Manufacturing Market Revenue
(US$ Mn) and Forecasts, By Platform
13.6.2.2.1. Mammalian
13.6.2.2.2. Microbial
13.6.2.3. The UK Biopharmaceutical Contract Manufacturing Market Revenue
(US$ Mn) and Forecasts, By Microbial
13.6.2.3.1. Growth Factors
13.6.2.3.2. Interferons
13.6.2.3.3. Monoclonal Antibodies
13.6.2.3.4. Recombinant Hormones
13.6.2.3.5. Vaccines
13.6.2.3.6. Insulin
13.6.2.3.7. Others
13.6.2.4. The UK Biopharmaceutical Contract Manufacturing Market Revenue
(US$ Mn) and Forecasts, By Application
13.6.2.4.1. Clinical
13.6.2.4.2. Commercial
13.6.2.4.3. Active Pharmaceutical Ingredient (API)
13.6.2.4.4. Finish Product
13.6.3. Spain
13.6.3.1. Spain Biopharmaceutical Contract Manufacturing Market Revenue
(US$ Mn) and Forecasts, By Therapeutic Area
13.6.3.1.1. Autoimmune Diseases
13.6.3.1.2. Oncology
13.6.3.1.3. Metabolic Diseases
13.6.3.1.4. Ophthalmology
13.6.3.1.5. Cardiovascular Diseases
13.6.3.1.6. Infectious Diseases
13.6.3.1.7. Neurology
13.6.3.1.8. Respiratory Disorders
13.6.3.1.9. Others
13.6.3.2. Spain Biopharmaceutical Contract Manufacturing Market Revenue
(US$ Mn) and Forecasts, By Platform
13.6.3.2.1. Mammalian
13.6.3.2.2. Microbial
13.6.3.3. Spain Biopharmaceutical Contract Manufacturing Market Revenue
(US$ Mn) and Forecasts, By Microbial
13.6.3.3.1. Growth Factors
13.6.3.3.2. Interferons
13.6.3.3.3. Monoclonal Antibodies
13.6.3.3.4. Recombinant Hormones
13.6.3.3.5. Vaccines
13.6.3.3.6. Insulin
13.6.3.3.7. Others
13.6.3.4. Spain Biopharmaceutical Contract Manufacturing Market Revenue
(US$ Mn) and Forecasts, By Application
13.6.3.4.1. Clinical
13.6.3.4.2. Commercial
13.6.3.4.3. Active Pharmaceutical Ingredient (API)
13.6.3.4.4. Finish Product
13.6.4. Germany
13.6.4.1. Germany Biopharmaceutical Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Therapeutic Area
13.6.4.1.1. Autoimmune Diseases
13.6.4.1.2. Oncology
13.6.4.1.3. Metabolic Diseases
13.6.4.1.4. Ophthalmology
13.6.4.1.5. Cardiovascular Diseases
13.6.4.1.6. Infectious Diseases
13.6.4.1.7. Neurology
13.6.4.1.8. Respiratory Disorders
13.6.4.1.9. Others
13.6.4.2. Germany Biopharmaceutical Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Platform
13.6.4.2.1. Mammalian
13.6.4.2.2. Microbial
13.6.4.3. Germany Biopharmaceutical Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Microbial
13.6.4.3.1. Growth Factors
13.6.4.3.2. Interferons
13.6.4.3.3. Monoclonal Antibodies
13.6.4.3.4. Recombinant Hormones
13.6.4.3.5. Vaccines
13.6.4.3.6. Insulin
13.6.4.3.7. Others
13.6.4.4. Germany Biopharmaceutical Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Application
13.6.4.4.1. Clinical
13.6.4.4.2. Commercial
13.6.4.4.3. Active Pharmaceutical Ingredient (API)
13.6.4.4.4. Finish Product
13.6.5. Italy
13.6.5.1. Italy Biopharmaceutical Contract Manufacturing Market Revenue
(US$ Mn) and Forecasts, By Therapeutic Area
13.6.5.1.1. Autoimmune Diseases
13.6.5.1.2. Oncology
13.6.5.1.3. Metabolic Diseases
13.6.5.1.4. Ophthalmology
13.6.5.1.5. Cardiovascular Diseases
13.6.5.1.6. Infectious Diseases
13.6.5.1.7. Neurology
13.6.5.1.8. Respiratory Disorders
13.6.5.1.9. Others
13.6.5.2. Italy Biopharmaceutical Contract Manufacturing Market Revenue
(US$ Mn) and Forecasts, By Platform
13.6.5.2.1. Mammalian
13.6.5.2.2. Microbial
13.6.5.3. Italy Biopharmaceutical Contract Manufacturing Market Revenue
(US$ Mn) and Forecasts, By Microbial
13.6.5.3.1. Growth Factors
13.6.5.3.2. Interferons
13.6.5.3.3. Monoclonal Antibodies
13.6.5.3.4. Recombinant Hormones
13.6.5.3.5. Vaccines
13.6.5.3.6. Insulin
13.6.5.3.7. Others
13.6.5.4. Italy Biopharmaceutical Contract Manufacturing Market Revenue
(US$ Mn) and Forecasts, By Application
13.6.5.4.1. Clinical
13.6.5.4.2. Commercial
13.6.5.4.3. Active Pharmaceutical Ingredient (API)
13.6.5.4.4. Finish Product
13.6.6. Nordic
Countries
13.6.6.1. Nordic Countries Biopharmaceutical Contract Manufacturing
Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area
13.6.6.1.1. Autoimmune Diseases
13.6.6.1.2. Oncology
13.6.6.1.3. Metabolic Diseases
13.6.6.1.4. Ophthalmology
13.6.6.1.5. Cardiovascular Diseases
13.6.6.1.6. Infectious Diseases
13.6.6.1.7. Neurology
13.6.6.1.8. Respiratory Disorders
13.6.6.1.9. Others
13.6.6.2. Nordic Countries Biopharmaceutical Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Platform
13.6.6.2.1. Mammalian
13.6.6.2.2. Microbial
13.6.6.3. Nordic Countries Biopharmaceutical Contract Manufacturing
Market Revenue (US$ Mn) and Forecasts, By Microbial
13.6.6.3.1. Growth Factors
13.6.6.3.2. Interferons
13.6.6.3.3. Monoclonal Antibodies
13.6.6.3.4. Recombinant Hormones
13.6.6.3.5. Vaccines
13.6.6.3.6. Insulin
13.6.6.3.7. Others
13.6.6.4. Nordic Countries Biopharmaceutical Contract Manufacturing
Market Revenue (US$ Mn) and Forecasts, By Application
13.6.6.4.1. Clinical
13.6.6.4.2. Commercial
13.6.6.4.3. Active Pharmaceutical Ingredient (API)
13.6.6.4.4. Finish Product
13.6.6.5. Nordic Countries Biopharmaceutical Contract Manufacturing
Market Revenue (US$ Mn) and Forecasts, By Country
13.6.6.5.1. Denmark
13.6.6.5.2. Finland
13.6.6.5.3. Iceland
13.6.6.5.4. Sweden
13.6.6.5.5. Norway
13.6.7. Benelux
Union
13.6.7.1. Benelux Union Biopharmaceutical Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Therapeutic Area
13.6.7.1.1. Autoimmune Diseases
13.6.7.1.2. Oncology
13.6.7.1.3. Metabolic Diseases
13.6.7.1.4. Ophthalmology
13.6.7.1.5. Cardiovascular Diseases
13.6.7.1.6. Infectious Diseases
13.6.7.1.7. Neurology
13.6.7.1.8. Respiratory Disorders
13.6.7.1.9. Others
13.6.7.2. Benelux Union Biopharmaceutical Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Platform
13.6.7.2.1. Mammalian
13.6.7.2.2. Microbial
13.6.7.3. Benelux Union Biopharmaceutical Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Microbial
13.6.7.3.1. Growth Factors
13.6.7.3.2. Interferons
13.6.7.3.3. Monoclonal Antibodies
13.6.7.3.4. Recombinant Hormones
13.6.7.3.5. Vaccines
13.6.7.3.6. Insulin
13.6.7.3.7. Others
13.6.7.4. Benelux Union Biopharmaceutical Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Application
13.6.7.4.1. Clinical
13.6.7.4.2. Commercial
13.6.7.4.3. Active Pharmaceutical Ingredient (API)
13.6.7.4.4. Finish Product
13.6.7.5. Benelux Union Biopharmaceutical Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Country
13.6.7.5.1. Belgium
13.6.7.5.2. The Netherlands
13.6.7.5.3. Luxembourg
13.6.8. Rest of
Europe
13.6.8.1. Rest of Europe Biopharmaceutical Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Therapeutic Area
13.6.8.1.1. Autoimmune Diseases
13.6.8.1.2. Oncology
13.6.8.1.3. Metabolic Diseases
13.6.8.1.4. Ophthalmology
13.6.8.1.5. Cardiovascular Diseases
13.6.8.1.6. Infectious Diseases
13.6.8.1.7. Neurology
13.6.8.1.8. Respiratory Disorders
13.6.8.1.9. Others
13.6.8.2. Rest of Europe Biopharmaceutical Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Platform
13.6.8.2.1. Mammalian
13.6.8.2.2. Microbial
13.6.8.3. Rest of Europe Biopharmaceutical Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Microbial
13.6.8.3.1. Growth Factors
13.6.8.3.2. Interferons
13.6.8.3.3. Monoclonal Antibodies
13.6.8.3.4. Recombinant Hormones
13.6.8.3.5. Vaccines
13.6.8.3.6. Insulin
13.6.8.3.7. Others
13.6.8.4. Rest of Europe Biopharmaceutical Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Application
13.6.8.4.1. Clinical
13.6.8.4.2. Commercial
13.6.8.4.3. Active Pharmaceutical Ingredient (API)
13.6.8.4.4. Finish Product
13.7. Key
Segment for Channeling Investments
13.7.1. By
Country
13.7.2. By
Therapeutic Area
13.7.3. By
Platform
13.7.4. By
Microbial
13.7.5. By
Application
14.
Asia Pacific
Biopharmaceutical Contract Manufacturing Market Analysis and Forecasts, 2019 -
2027
14.1. Overview
14.1.1. Asia
Pacific Biopharmaceutical Contract Manufacturing Market Revenue (US$ Mn)
14.2. Asia
Pacific Biopharmaceutical Contract Manufacturing Market Revenue (US$ Mn) and
Forecasts, By Therapeutic Area
14.2.1. Autoimmune
Diseases
14.2.2. Oncology
14.2.3. Metabolic
Diseases
14.2.4. Ophthalmology
14.2.5. Cardiovascular
Diseases
14.2.6. Infectious
Diseases
14.2.7. Neurology
14.2.8. Respiratory
Disorders
14.2.9. Others
14.3. Asia
Pacific Biopharmaceutical Contract Manufacturing Market Revenue (US$ Mn) and
Forecasts, By Platform
14.3.1. Mammalian
14.3.2. Microbial
14.4. Asia
Pacific Biopharmaceutical Contract Manufacturing Market Revenue (US$ Mn) and
Forecasts, By Microbial
14.4.1. Growth
Factors
14.4.2. Interferons
14.4.3. Monoclonal
Antibodies
14.4.4. Recombinant
Hormones
14.4.5. Vaccines
14.4.6. Insulin
14.4.7. Others
14.5. Asia
Pacific Biopharmaceutical Contract Manufacturing Market Revenue (US$ Mn) and
Forecasts, By Application
14.5.1. Clinical
14.5.2. Commercial
14.5.3. Active
Pharmaceutical Ingredient (API)
14.5.4. Finish
Product
14.6. Asia
Pacific Biopharmaceutical Contract Manufacturing Market Revenue (US$ Mn) and
Forecasts, By Country
14.6.1. China
14.6.1.1. China Biopharmaceutical Contract Manufacturing Market Revenue
(US$ Mn) and Forecasts, By Therapeutic Area
14.6.1.1.1. Autoimmune Diseases
14.6.1.1.2. Oncology
14.6.1.1.3. Metabolic Diseases
14.6.1.1.4. Ophthalmology
14.6.1.1.5. Cardiovascular Diseases
14.6.1.1.6. Infectious Diseases
14.6.1.1.7. Neurology
14.6.1.1.8. Respiratory Disorders
14.6.1.1.9. Others
14.6.1.2. China Biopharmaceutical Contract Manufacturing Market Revenue
(US$ Mn) and Forecasts, By Platform
14.6.1.2.1. Mammalian
14.6.1.2.2. Microbial
14.6.1.3. China Biopharmaceutical Contract Manufacturing Market Revenue
(US$ Mn) and Forecasts, By Microbial
14.6.1.3.1. Growth Factors
14.6.1.3.2. Interferons
14.6.1.3.3. Monoclonal Antibodies
14.6.1.3.4. Recombinant Hormones
14.6.1.3.5. Vaccines
14.6.1.3.6. Insulin
14.6.1.3.7. Others
14.6.1.4. China Biopharmaceutical Contract Manufacturing Market Revenue
(US$ Mn) and Forecasts, By Application
14.6.1.4.1. Clinical
14.6.1.4.2. Commercial
14.6.1.4.3. Active Pharmaceutical Ingredient (API)
14.6.1.4.4. Finish Product
14.6.2. Japan
14.6.2.1. Japan Biopharmaceutical Contract Manufacturing Market Revenue
(US$ Mn) and Forecasts, By Therapeutic Area
14.6.2.1.1. Autoimmune Diseases
14.6.2.1.2. Oncology
14.6.2.1.3. Metabolic Diseases
14.6.2.1.4. Ophthalmology
14.6.2.1.5. Cardiovascular Diseases
14.6.2.1.6. Infectious Diseases
14.6.2.1.7. Neurology
14.6.2.1.8. Respiratory Disorders
14.6.2.1.9. Others
14.6.2.2. Japan Biopharmaceutical Contract Manufacturing Market Revenue
(US$ Mn) and Forecasts, By Platform
14.6.2.2.1. Mammalian
14.6.2.2.2. Microbial
14.6.2.3. Japan Biopharmaceutical Contract Manufacturing Market Revenue
(US$ Mn) and Forecasts, By Microbial
14.6.2.3.1. Growth Factors
14.6.2.3.2. Interferons
14.6.2.3.3. Monoclonal Antibodies
14.6.2.3.4. Recombinant Hormones
14.6.2.3.5. Vaccines
14.6.2.3.6. Insulin
14.6.2.3.7. Others
14.6.2.4. Japan Biopharmaceutical Contract Manufacturing Market Revenue
(US$ Mn) and Forecasts, By Application
14.6.2.4.1. Clinical
14.6.2.4.2. Commercial
14.6.2.4.3. Active Pharmaceutical Ingredient (API)
14.6.2.4.4. Finish Product
14.6.3. India
14.6.3.1. India Biopharmaceutical Contract Manufacturing Market Revenue
(US$ Mn) and Forecasts, By Therapeutic Area
14.6.3.1.1. Autoimmune Diseases
14.6.3.1.2. Oncology
14.6.3.1.3. Metabolic Diseases
14.6.3.1.4. Ophthalmology
14.6.3.1.5. Cardiovascular Diseases
14.6.3.1.6. Infectious Diseases
14.6.3.1.7. Neurology
14.6.3.1.8. Respiratory Disorders
14.6.3.1.9. Others
14.6.3.2. India Biopharmaceutical Contract Manufacturing Market Revenue
(US$ Mn) and Forecasts, By Platform
14.6.3.2.1. Mammalian
14.6.3.2.2. Microbial
14.6.3.3. India Biopharmaceutical Contract Manufacturing Market Revenue
(US$ Mn) and Forecasts, By Microbial
14.6.3.3.1. Growth Factors
14.6.3.3.2. Interferons
14.6.3.3.3. Monoclonal Antibodies
14.6.3.3.4. Recombinant Hormones
14.6.3.3.5. Vaccines
14.6.3.3.6. Insulin
14.6.3.3.7. Others
14.6.3.4. India Biopharmaceutical Contract Manufacturing Market Revenue
(US$ Mn) and Forecasts, By Application
14.6.3.4.1. Clinical
14.6.3.4.2. Commercial
14.6.3.4.3. Active Pharmaceutical Ingredient (API)
14.6.3.4.4. Finish Product
14.6.4. New
Zealand
14.6.4.1. New Zealand Biopharmaceutical Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Therapeutic Area
14.6.4.1.1. Autoimmune Diseases
14.6.4.1.2. Oncology
14.6.4.1.3. Metabolic Diseases
14.6.4.1.4. Ophthalmology
14.6.4.1.5. Cardiovascular Diseases
14.6.4.1.6. Infectious Diseases
14.6.4.1.7. Neurology
14.6.4.1.8. Respiratory Disorders
14.6.4.1.9. Others
14.6.4.2. New Zealand Biopharmaceutical Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Platform
14.6.4.2.1. Mammalian
14.6.4.2.2. Microbial
14.6.4.3. New Zealand Biopharmaceutical Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Microbial
14.6.4.3.1. Growth Factors
14.6.4.3.2. Interferons
14.6.4.3.3. Monoclonal Antibodies
14.6.4.3.4. Recombinant Hormones
14.6.4.3.5. Vaccines
14.6.4.3.6. Insulin
14.6.4.3.7. Others
14.6.4.4. New Zealand Biopharmaceutical Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Application
14.6.4.4.1. Clinical
14.6.4.4.2. Commercial
14.6.4.4.3. Active Pharmaceutical Ingredient (API)
14.6.4.4.4. Finish Product
14.6.5. Australia
14.6.5.1. Australia Biopharmaceutical Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Therapeutic Area
14.6.5.1.1. Autoimmune Diseases
14.6.5.1.2. Oncology
14.6.5.1.3. Metabolic Diseases
14.6.5.1.4. Ophthalmology
14.6.5.1.5. Cardiovascular Diseases
14.6.5.1.6. Infectious Diseases
14.6.5.1.7. Neurology
14.6.5.1.8. Respiratory Disorders
14.6.5.1.9. Others
14.6.5.2. Australia Biopharmaceutical Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Platform
14.6.5.2.1. Mammalian
14.6.5.2.2. Microbial
14.6.5.3. Australia Biopharmaceutical Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Microbial
14.6.5.3.1. Growth Factors
14.6.5.3.2. Interferons
14.6.5.3.3. Monoclonal Antibodies
14.6.5.3.4. Recombinant Hormones
14.6.5.3.5. Vaccines
14.6.5.3.6. Insulin
14.6.5.3.7. Others
14.6.5.4. Australia Biopharmaceutical Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Application
14.6.5.4.1. Clinical
14.6.5.4.2. Commercial
14.6.5.4.3. Active Pharmaceutical Ingredient (API)
14.6.5.4.4. Finish Product
14.6.6. South
Korea
14.6.6.1. South Korea Biopharmaceutical Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Therapeutic Area
14.6.6.1.1. Autoimmune Diseases
14.6.6.1.2. Oncology
14.6.6.1.3. Metabolic Diseases
14.6.6.1.4. Ophthalmology
14.6.6.1.5. Cardiovascular Diseases
14.6.6.1.6. Infectious Diseases
14.6.6.1.7. Neurology
14.6.6.1.8. Respiratory Disorders
14.6.6.1.9. Others
14.6.6.2. South Korea Biopharmaceutical Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Platform
14.6.6.2.1. Mammalian
14.6.6.2.2. Microbial
14.6.6.3. South Korea Biopharmaceutical Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Microbial
14.6.6.3.1. Growth Factors
14.6.6.3.2. Interferons
14.6.6.3.3. Monoclonal Antibodies
14.6.6.3.4. Recombinant Hormones
14.6.6.3.5. Vaccines
14.6.6.3.6. Insulin
14.6.6.3.7. Others
14.6.6.4. South Korea Biopharmaceutical Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Application
14.6.6.4.1. Clinical
14.6.6.4.2. Commercial
14.6.6.4.3. Active Pharmaceutical Ingredient (API)
14.6.6.4.4. Finish Product
14.6.7. Southeast
Asia
14.6.7.1. Southeast Asia Biopharmaceutical Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Therapeutic Area
14.6.7.1.1. Autoimmune Diseases
14.6.7.1.2. Oncology
14.6.7.1.3. Metabolic Diseases
14.6.7.1.4. Ophthalmology
14.6.7.1.5. Cardiovascular Diseases
14.6.7.1.6. Infectious Diseases
14.6.7.1.7. Neurology
14.6.7.1.8. Respiratory Disorders
14.6.7.1.9. Others
14.6.7.2. Southeast Asia Biopharmaceutical Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Platform
14.6.7.2.1. Mammalian
14.6.7.2.2. Microbial
14.6.7.3. Southeast Asia Biopharmaceutical Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Microbial
14.6.7.3.1. Growth Factors
14.6.7.3.2. Interferons
14.6.7.3.3. Monoclonal Antibodies
14.6.7.3.4. Recombinant Hormones
14.6.7.3.5. Vaccines
14.6.7.3.6. Insulin
14.6.7.3.7. Others
14.6.7.4. Southeast Asia Biopharmaceutical Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Application
14.6.7.4.1. Clinical
14.6.7.4.2. Commercial
14.6.7.4.3. Active Pharmaceutical Ingredient (API)
14.6.7.4.4. Finish Product
14.6.7.5. Southeast Asia Biopharmaceutical Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Country
14.6.7.5.1. Indonesia
14.6.7.5.2. Thailand
14.6.7.5.3. Malaysia
14.6.7.5.4. Singapore
14.6.7.5.5. Rest of Southeast Asia
14.6.8. Rest of
Asia Pacific
14.6.8.1. Rest of Asia Pacific Biopharmaceutical Contract Manufacturing
Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area
14.6.8.1.1. Autoimmune Diseases
14.6.8.1.2. Oncology
14.6.8.1.3. Metabolic Diseases
14.6.8.1.4. Ophthalmology
14.6.8.1.5. Cardiovascular Diseases
14.6.8.1.6. Infectious Diseases
14.6.8.1.7. Neurology
14.6.8.1.8. Respiratory Disorders
14.6.8.1.9. Others
14.6.8.2. Rest of Asia Pacific Biopharmaceutical Contract Manufacturing
Market Revenue (US$ Mn) and Forecasts, By Platform
14.6.8.2.1. Mammalian
14.6.8.2.2. Microbial
14.6.8.3. Rest of Asia Pacific Biopharmaceutical Contract Manufacturing
Market Revenue (US$ Mn) and Forecasts, By Microbial
14.6.8.3.1. Growth Factors
14.6.8.3.2. Interferons
14.6.8.3.3. Monoclonal Antibodies
14.6.8.3.4. Recombinant Hormones
14.6.8.3.5. Vaccines
14.6.8.3.6. Insulin
14.6.8.3.7. Others
14.6.8.4. Rest of Asia Pacific Biopharmaceutical Contract Manufacturing
Market Revenue (US$ Mn) and Forecasts, By Application
14.6.8.4.1. Clinical
14.6.8.4.2. Commercial
14.6.8.4.3. Active Pharmaceutical Ingredient (API)
14.6.8.4.4. Finish Product
14.7. Key
Segment for Channeling Investments
14.7.1. By
Country
14.7.2. By
Therapeutic Area
14.7.3. By
Platform
14.7.4. By
Microbial
14.7.5. By
Application
15.
Middle East and Africa
Biopharmaceutical Contract Manufacturing Market Analysis and Forecasts, 2019 -
2027
15.1. Overview
15.1.1. Middle
East and Africa Biopharmaceutical Contract Manufacturing Market Revenue (US$
Mn)
15.2. Middle
East and Africa Biopharmaceutical Contract Manufacturing Market Revenue (US$
Mn) and Forecasts, By Therapeutic Area
15.2.1. Autoimmune
Diseases
15.2.2. Oncology
15.2.3. Metabolic
Diseases
15.2.4. Ophthalmology
15.2.5. Cardiovascular
Diseases
15.2.6. Infectious
Diseases
15.2.7. Neurology
15.2.8. Respiratory
Disorders
15.2.9. Others
15.3. Middle
East and Africa Biopharmaceutical Contract Manufacturing Market Revenue (US$
Mn) and Forecasts, By Platform
15.3.1. Mammalian
15.3.2. Microbial
15.4. Middle
East and Africa Biopharmaceutical Contract Manufacturing Market Revenue (US$
Mn) and Forecasts, By Microbial
15.4.1. Growth
Factors
15.4.2. Interferons
15.4.3. Monoclonal
Antibodies
15.4.4. Recombinant
Hormones
15.4.5. Vaccines
15.4.6. Insulin
15.4.7. Others
15.5. Middle
East and Africa Biopharmaceutical Contract Manufacturing Market Revenue (US$
Mn) and Forecasts, By Application
15.5.1. Clinical
15.5.2. Commercial
15.5.3. Active
Pharmaceutical Ingredient (API)
15.5.4. Finish
Product
15.6. Middle
East and Africa Biopharmaceutical Contract Manufacturing Market Revenue (US$
Mn) and Forecasts, By Country
15.6.1. Saudi
Arabia
15.6.1.1. Saudi Arabia Biopharmaceutical Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Therapeutic Area
15.6.1.1.1. Autoimmune Diseases
15.6.1.1.2. Oncology
15.6.1.1.3. Metabolic Diseases
15.6.1.1.4. Ophthalmology
15.6.1.1.5. Cardiovascular Diseases
15.6.1.1.6. Infectious Diseases
15.6.1.1.7. Neurology
15.6.1.1.8. Respiratory Disorders
15.6.1.1.9. Others
15.6.1.2. Saudi Arabia Biopharmaceutical Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Platform
15.6.1.2.1. Mammalian
15.6.1.2.2. Microbial
15.6.1.3. Saudi Arabia Biopharmaceutical Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Microbial
15.6.1.3.1. Growth Factors
15.6.1.3.2. Interferons
15.6.1.3.3. Monoclonal Antibodies
15.6.1.3.4. Recombinant Hormones
15.6.1.3.5. Vaccines
15.6.1.3.6. Insulin
15.6.1.3.7. Others
15.6.1.4. Saudi Arabia Biopharmaceutical Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Application
15.6.1.4.1. Clinical
15.6.1.4.2. Commercial
15.6.1.4.3. Active Pharmaceutical Ingredient (API)
15.6.1.4.4. Finish Product
15.6.2. UAE
15.6.2.1. UAE Biopharmaceutical Contract Manufacturing Market Revenue
(US$ Mn) and Forecasts, By Therapeutic Area
15.6.2.1.1. Autoimmune Diseases
15.6.2.1.2. Oncology
15.6.2.1.3. Metabolic Diseases
15.6.2.1.4. Ophthalmology
15.6.2.1.5. Cardiovascular Diseases
15.6.2.1.6. Infectious Diseases
15.6.2.1.7. Neurology
15.6.2.1.8. Respiratory Disorders
15.6.2.1.9. Others
15.6.2.2. UAE Biopharmaceutical Contract Manufacturing Market Revenue
(US$ Mn) and Forecasts, By Platform
15.6.2.2.1. Mammalian
15.6.2.2.2. Microbial
15.6.2.3. UAE Biopharmaceutical Contract Manufacturing Market Revenue
(US$ Mn) and Forecasts, By Microbial
15.6.2.3.1. Growth Factors
15.6.2.3.2. Interferons
15.6.2.3.3. Monoclonal Antibodies
15.6.2.3.4. Recombinant Hormones
15.6.2.3.5. Vaccines
15.6.2.3.6. Insulin
15.6.2.3.7. Others
15.6.2.4. UAE Biopharmaceutical Contract Manufacturing Market Revenue
(US$ Mn) and Forecasts, By Application
15.6.2.4.1. Clinical
15.6.2.4.2. Commercial
15.6.2.4.3. Active Pharmaceutical Ingredient (API)
15.6.2.4.4. Finish Product
15.6.3. Egypt
15.6.3.1. Egypt Biopharmaceutical Contract Manufacturing Market Revenue
(US$ Mn) and Forecasts, By Therapeutic Area
15.6.3.1.1. Autoimmune Diseases
15.6.3.1.2. Oncology
15.6.3.1.3. Metabolic Diseases
15.6.3.1.4. Ophthalmology
15.6.3.1.5. Cardiovascular Diseases
15.6.3.1.6. Infectious Diseases
15.6.3.1.7. Neurology
15.6.3.1.8. Respiratory Disorders
15.6.3.1.9. Others
15.6.3.2. Egypt Biopharmaceutical Contract Manufacturing Market Revenue
(US$ Mn) and Forecasts, By Platform
15.6.3.2.1. Mammalian
15.6.3.2.2. Microbial
15.6.3.3. Egypt Biopharmaceutical Contract Manufacturing Market Revenue
(US$ Mn) and Forecasts, By Microbial
15.6.3.3.1. Growth Factors
15.6.3.3.2. Interferons
15.6.3.3.3. Monoclonal Antibodies
15.6.3.3.4. Recombinant Hormones
15.6.3.3.5. Vaccines
15.6.3.3.6. Insulin
15.6.3.3.7. Others
15.6.3.4. Egypt Biopharmaceutical Contract Manufacturing Market Revenue
(US$ Mn) and Forecasts, By Application
15.6.3.4.1. Clinical
15.6.3.4.2. Commercial
15.6.3.4.3. Active Pharmaceutical Ingredient (API)
15.6.3.4.4. Finish Product
15.6.4. Kuwait
15.6.4.1. Kuwait Biopharmaceutical Contract Manufacturing Market Revenue
(US$ Mn) and Forecasts, By Therapeutic Area
15.6.4.1.1. Autoimmune Diseases
15.6.4.1.2. Oncology
15.6.4.1.3. Metabolic Diseases
15.6.4.1.4. Ophthalmology
15.6.4.1.5. Cardiovascular Diseases
15.6.4.1.6. Infectious Diseases
15.6.4.1.7. Neurology
15.6.4.1.8. Respiratory Disorders
15.6.4.1.9. Others
15.6.4.2. Kuwait Biopharmaceutical Contract Manufacturing Market Revenue
(US$ Mn) and Forecasts, By Platform
15.6.4.2.1. Mammalian
15.6.4.2.2. Microbial
15.6.4.3. Kuwait Biopharmaceutical Contract Manufacturing Market Revenue
(US$ Mn) and Forecasts, By Microbial
15.6.4.3.1. Growth Factors
15.6.4.3.2. Interferons
15.6.4.3.3. Monoclonal Antibodies
15.6.4.3.4. Recombinant Hormones
15.6.4.3.5. Vaccines
15.6.4.3.6. Insulin
15.6.4.3.7. Others
15.6.4.4. Kuwait Biopharmaceutical Contract Manufacturing Market Revenue
(US$ Mn) and Forecasts, By Application
15.6.4.4.1. Clinical
15.6.4.4.2. Commercial
15.6.4.4.3. Active Pharmaceutical Ingredient (API)
15.6.4.4.4. Finish Product
15.6.5. South
Africa
15.6.5.1. South Africa Biopharmaceutical Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Therapeutic Area
15.6.5.1.1. Autoimmune Diseases
15.6.5.1.2. Oncology
15.6.5.1.3. Metabolic Diseases
15.6.5.1.4. Ophthalmology
15.6.5.1.5. Cardiovascular Diseases
15.6.5.1.6. Infectious Diseases
15.6.5.1.7. Neurology
15.6.5.1.8. Respiratory Disorders
15.6.5.1.9. Others
15.6.5.2. South Africa Biopharmaceutical Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Platform
15.6.5.2.1. Mammalian
15.6.5.2.2. Microbial
15.6.5.3. South Africa Biopharmaceutical Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Microbial
15.6.5.3.1. Growth Factors
15.6.5.3.2. Interferons
15.6.5.3.3. Monoclonal Antibodies
15.6.5.3.4. Recombinant Hormones
15.6.5.3.5. Vaccines
15.6.5.3.6. Insulin
15.6.5.3.7. Others
15.6.5.4. South Africa Biopharmaceutical Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Application
15.6.5.4.1. Clinical
15.6.5.4.2. Commercial
15.6.5.4.3. Active Pharmaceutical Ingredient (API)
15.6.5.4.4. Finish Product
15.6.6. Rest of
Middle East & Africa
15.6.6.1. Rest of Middle East & Africa Biopharmaceutical Contract
Manufacturing Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area
15.6.6.1.1. Autoimmune Diseases
15.6.6.1.2. Oncology
15.6.6.1.3. Metabolic Diseases
15.6.6.1.4. Ophthalmology
15.6.6.1.5. Cardiovascular Diseases
15.6.6.1.6. Infectious Diseases
15.6.6.1.7. Neurology
15.6.6.1.8. Respiratory Disorders
15.6.6.1.9. Others
15.6.6.2. Rest of Middle East & Africa Biopharmaceutical Contract
Manufacturing Market Revenue (US$ Mn) and Forecasts, By Platform
15.6.6.2.1. Mammalian
15.6.6.2.2. Microbial
15.6.6.3. Rest of Middle East & Africa Biopharmaceutical Contract
Manufacturing Market Revenue (US$ Mn) and Forecasts, By Microbial
15.6.6.3.1. Growth Factors
15.6.6.3.2. Interferons
15.6.6.3.3. Monoclonal Antibodies
15.6.6.3.4. Recombinant Hormones
15.6.6.3.5. Vaccines
15.6.6.3.6. Insulin
15.6.6.3.7. Others
15.6.6.4. Rest of Middle East & Africa Biopharmaceutical Contract
Manufacturing Market Revenue (US$ Mn) and Forecasts, By Application
15.6.6.4.1. Clinical
15.6.6.4.2. Commercial
15.6.6.4.3. Active Pharmaceutical Ingredient (API)
15.6.6.4.4. Finish Product
15.7. Key
Segment for Channeling Investments
15.7.1. By
Country
15.7.2. By
Therapeutic Area
15.7.3. By
Platform
15.7.4. By
Microbial
15.7.5. By
Application
16.
Latin America
Biopharmaceutical Contract Manufacturing Market Analysis and Forecasts, 2019 -
2027
16.1. Overview
16.1.1. Latin
America Biopharmaceutical Contract Manufacturing Market Revenue (US$ Mn)
16.2. Latin
America Biopharmaceutical Contract Manufacturing Market Revenue (US$ Mn) and
Forecasts, By Therapeutic Area
16.2.1. Autoimmune
Diseases
16.2.2. Oncology
16.2.3. Metabolic
Diseases
16.2.4. Ophthalmology
16.2.5. Cardiovascular
Diseases
16.2.6. Infectious
Diseases
16.2.7. Neurology
16.2.8. Respiratory
Disorders
16.2.9. Others
16.3. Latin
America Biopharmaceutical Contract Manufacturing Market Revenue (US$ Mn) and
Forecasts, By Platform
16.3.1. Mammalian
16.3.2. Microbial
16.4. Latin
America Biopharmaceutical Contract Manufacturing Market Revenue (US$ Mn) and
Forecasts, By Microbial
16.4.1. Growth
Factors
16.4.2. Interferons
16.4.3. Monoclonal
Antibodies
16.4.4. Recombinant
Hormones
16.4.5. Vaccines
16.4.6. Insulin
16.4.7. Others
16.5. Latin
America Biopharmaceutical Contract Manufacturing Market Revenue (US$ Mn) and
Forecasts, By Application
16.5.1. Clinical
16.5.2. Commercial
16.5.3. Active
Pharmaceutical Ingredient (API)
16.5.4. Finish
Product
16.6. Latin
America Biopharmaceutical Contract Manufacturing Market Revenue (US$ Mn) and
Forecasts, By Country
16.6.1. Brazil
16.6.1.1. Brazil Biopharmaceutical Contract Manufacturing Market Revenue
(US$ Mn) and Forecasts, By Therapeutic Area
16.6.1.1.1. Autoimmune Diseases
16.6.1.1.2. Oncology
16.6.1.1.3. Metabolic Diseases
16.6.1.1.4. Ophthalmology
16.6.1.1.5. Cardiovascular Diseases
16.6.1.1.6. Infectious Diseases
16.6.1.1.7. Neurology
16.6.1.1.8. Respiratory Disorders
16.6.1.1.9. Others
16.6.1.2. Brazil Biopharmaceutical Contract Manufacturing Market Revenue
(US$ Mn) and Forecasts, By Platform
16.6.1.2.1. Mammalian
16.6.1.2.2. Microbial
16.6.1.3. Brazil Biopharmaceutical Contract Manufacturing Market Revenue
(US$ Mn) and Forecasts, By Microbial
16.6.1.3.1. Growth Factors
16.6.1.3.2. Interferons
16.6.1.3.3. Monoclonal Antibodies
16.6.1.3.4. Recombinant Hormones
16.6.1.3.5. Vaccines
16.6.1.3.6. Insulin
16.6.1.3.7. Others
16.6.1.4. Brazil Biopharmaceutical Contract Manufacturing Market Revenue
(US$ Mn) and Forecasts, By Application
16.6.1.4.1. Clinical
16.6.1.4.2. Commercial
16.6.1.4.3. Active Pharmaceutical Ingredient (API)
16.6.1.4.4. Finish Product
16.6.2. Argentina
16.6.2.1. Argentina Biopharmaceutical Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Therapeutic Area
16.6.2.1.1. Autoimmune Diseases
16.6.2.1.2. Oncology
16.6.2.1.3. Metabolic Diseases
16.6.2.1.4. Ophthalmology
16.6.2.1.5. Cardiovascular Diseases
16.6.2.1.6. Infectious Diseases
16.6.2.1.7. Neurology
16.6.2.1.8. Respiratory Disorders
16.6.2.1.9. Others
16.6.2.2. Argentina Biopharmaceutical Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Platform
16.6.2.2.1. Mammalian
16.6.2.2.2. Microbial
16.6.2.3. Argentina Biopharmaceutical Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Microbial
16.6.2.3.1. Growth Factors
16.6.2.3.2. Interferons
16.6.2.3.3. Monoclonal Antibodies
16.6.2.3.4. Recombinant Hormones
16.6.2.3.5. Vaccines
16.6.2.3.6. Insulin
16.6.2.3.7. Others
16.6.2.4. Argentina Biopharmaceutical Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Application
16.6.2.4.1. Clinical
16.6.2.4.2. Commercial
16.6.2.4.3. Active Pharmaceutical Ingredient (API)
16.6.2.4.4. Finish Product
16.6.3. Rest of
Latin America
16.6.3.1. Rest of Latin America Biopharmaceutical Contract Manufacturing
Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area
16.6.3.1.1. Autoimmune Diseases
16.6.3.1.2. Oncology
16.6.3.1.3. Metabolic Diseases
16.6.3.1.4. Ophthalmology
16.6.3.1.5. Cardiovascular Diseases
16.6.3.1.6. Infectious Diseases
16.6.3.1.7. Neurology
16.6.3.1.8. Respiratory Disorders
16.6.3.1.9. Others
16.6.3.2. Rest of Latin America Biopharmaceutical Contract Manufacturing
Market Revenue (US$ Mn) and Forecasts, By Platform
16.6.3.2.1. Mammalian
16.6.3.2.2. Microbial
16.6.3.3. Rest of Latin America Biopharmaceutical Contract Manufacturing
Market Revenue (US$ Mn) and Forecasts, By Microbial
16.6.3.3.1. Growth Factors
16.6.3.3.2. Interferons
16.6.3.3.3. Monoclonal Antibodies
16.6.3.3.4. Recombinant Hormones
16.6.3.3.5. Vaccines
16.6.3.3.6. Insulin
16.6.3.3.7. Others
16.6.3.4. Rest of Latin America Biopharmaceutical Contract Manufacturing
Market Revenue (US$ Mn) and Forecasts, By Application
16.6.3.4.1. Clinical
16.6.3.4.2. Commercial
16.6.3.4.3. Active Pharmaceutical Ingredient (API)
16.6.3.4.4. Finish Product
16.7. Key
Segment for Channeling Investments
16.7.1. By
Country
16.7.2. By
Therapeutic Area
16.7.3. By
Platform
16.7.4. By
Microbial
16.7.5. By
Application
17.
Competitive Benchmarking
17.1. Market
Share Analysis, 2018
17.2. Global
Presence and Growth Strategies
17.2.1. Mergers
and Acquisitions
17.2.2. Product
Launches
17.2.3. Investments
Trends
17.2.4. R&D
Initiatives
18.
Player Profiles
18.1. AbbVie
Inc.
18.1.1. Company
Details
18.1.2. Company
Overview
18.1.3. Product
Offerings
18.1.4. Key
Developments
18.1.5. Financial
Analysis
18.1.6. SWOT
Analysis
18.1.7. Business
Strategies
18.2. Abzena
Ltd
18.2.1. Company
Details
18.2.2. Company
Overview
18.2.3. Product
Offerings
18.2.4. Key
Developments
18.2.5. Financial
Analysis
18.2.6. SWOT
Analysis
18.2.7. Business
Strategies
18.3. Ajinomoto
Bio-Pharma
18.3.1. Company
Details
18.3.2. Company
Overview
18.3.3. Product
Offerings
18.3.4. Key
Developments
18.3.5. Financial
Analysis
18.3.6. SWOT
Analysis
18.3.7. Business
Strategies
18.4. Baxter
Healthcare Corporation
18.4.1. Company
Details
18.4.2. Company
Overview
18.4.3. Product
Offerings
18.4.4. Key
Developments
18.4.5. Financial
Analysis
18.4.6. SWOT
Analysis
18.4.7. Business
Strategies
18.5. Boehringer
Ingelheim International GmbH
18.5.1. Company
Details
18.5.2. Company
Overview
18.5.3. Product
Offerings
18.5.4. Key
Developments
18.5.5. Financial
Analysis
18.5.6. SWOT
Analysis
18.5.7. Business
Strategies
18.6. Catalent,
Inc.
18.6.1. Company
Details
18.6.2. Company
Overview
18.6.3. Product
Offerings
18.6.4. Key
Developments
18.6.5. Financial
Analysis
18.6.6. SWOT
Analysis
18.6.7. Business
Strategies
18.7. Cytovance
Biologics
18.7.1. Company
Details
18.7.2. Company
Overview
18.7.3. Product
Offerings
18.7.4. Key
Developments
18.7.5. Financial
Analysis
18.7.6. SWOT
Analysis
18.7.7. Business
Strategies
18.8. FUJIFILM
Corporation
18.8.1. Company
Details
18.8.2. Company
Overview
18.8.3. Product
Offerings
18.8.4. Key Developments
18.8.5. Financial
Analysis
18.8.6. SWOT
Analysis
18.8.7. Business
Strategies
18.9. KBI
Biopharma
18.9.1. Company
Details
18.9.2. Company
Overview
18.9.3. Product
Offerings
18.9.4. Key
Developments
18.9.5. Financial
Analysis
18.9.6. SWOT
Analysis
18.9.7. Business
Strategies
18.10. Lonza
18.10.1. Company
Details
18.10.2. Company
Overview
18.10.3. Product
Offerings
18.10.4. Key
Developments
18.10.5. Financial
Analysis
18.10.6. SWOT
Analysis
18.10.7. Business
Strategies
18.11. ProBioGen
AG
18.11.1. Company
Details
18.11.2. Company
Overview
18.11.3. Product
Offerings
18.11.4. Key
Developments
18.11.5. Financial
Analysis
18.11.6. SWOT
Analysis
18.11.7. Business
Strategies
18.12. Rentschler
Biopharma SE
18.12.1. Company
Details
18.12.2. Company
Overview
18.12.3. Product
Offerings
18.12.4. Key
Developments
18.12.5. Financial
Analysis
18.12.6. SWOT
Analysis
18.12.7. Business
Strategies
18.13. Sai Life
Sciences Ltd.
18.13.1. Company
Details
18.13.2. Company
Overview
18.13.3. Product
Offerings
18.13.4. Key
Developments
18.13.5. Financial
Analysis
18.13.6. SWOT
Analysis
18.13.7. Business
Strategies
18.14. Samsung
Biologics Co., Ltd.
18.14.1. Company
Details
18.14.2. Company
Overview
18.14.3. Product
Offerings
18.14.4. Key
Developments
18.14.5. Financial
Analysis
18.14.6. SWOT
Analysis
18.14.7. Business
Strategies
18.15. Sandoz
International GmbH
18.15.1. Company
Details
18.15.2. Company
Overview
18.15.3. Product
Offerings
18.15.4. Key
Developments
18.15.5. Financial
Analysis
18.15.6. SWOT
Analysis
18.15.7. Business
Strategies
18.16. Thermo
Fisher Scientific Inc (Patheon)
18.16.1. Company
Details
18.16.2. Company
Overview
18.16.3. Product
Offerings
18.16.4. Key
Developments
18.16.5. Financial
Analysis
18.16.6. SWOT
Analysis
18.16.7. Business
Strategies
18.17. Vetter
18.17.1. Company
Details
18.17.2. Company
Overview
18.17.3. Product
Offerings
18.17.4. Key
Developments
18.17.5. Financial
Analysis
18.17.6. SWOT
Analysis
18.17.7. Business
Strategies
18.18. WuXi
Biologics
18.18.1. Company
Details
18.18.2. Company
Overview
18.18.3. Product
Offerings
18.18.4. Key
Developments
18.18.5. Financial
Analysis
18.18.6. SWOT
Analysis
18.18.7. Business
Strategies
19.
Key Findings
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.